AprilBio Completes 154.9 Billion Won Third-Party Allocation Capital Raise with Management Change Implications
AprilBio disclosed on July 23 that it completed a third-party allocation of 3,608,595 voting convertible preferred shares, raising 154,999,981,035 KRW.
The issuance price of 42,953 KRW is a 75% premium over the current market price of 24,500 KRW, but the new shares dilute existing shareholders by approximately 15% relative to outstanding shares.
The new shares are subject to a one-year lock-up, and a management change contract was signed on the same day, indicating potential governance changes.
[AI Summary]AprilBio completed a 154.9 billion won third-party allocation, diluting existing shareholders by ~15%. While the high issuance premium limits downside, the concurrent management change contract introduces governance uncertainty.
KOSDAQ Filing Information
Securities Issuance Result (Voluntary Disclosure) (Third-Party Allotment Paid-in Capital Increase - Non-Voting Convertible Preferred Shares)